New pill targets RET-Driven cancers in early trial

NCT ID NCT05451602

Recruiting now Disease control Sponsor: Sunshine Lake Pharma Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new oral drug called HEC169096 in people with advanced solid tumors, including thyroid cancer and non-small cell lung cancer, that have a specific RET gene change. The trial has two phases: the first finds the safest dose, and the second checks how well the drug shrinks tumors. About 456 participants will take part across multiple centers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HEC169096 (a RET inhibitor drug taken by mouth)
What this could lead to: If it works, this could offer a new treatment option for people with advanced solid tumors that have a specific RET gene change.
What could go wrong: This is an early-phase trial, so the drug may not work or could have side effects. It is only for people with certain RET gene changes, so it won't help everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm non-small cell lung carcinoma thyroid cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Show contact details

Locations

GuangDong Province Peoples Hospital
RECRUITING

Guangzhou, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.